This bill aims to amend title XI of the Social Security Act to equalize the negotiation period for small-molecule and biologic candidates under the Drug Price Negotiation Program. The legislation addresses the current disparity in negotiation timelines between these drug types. Specifically, the bill modifies the eligibility criteria for small-molecule drugs. While the 7-year negotiation period will remain for initial price applicability years 2026 and 2027, for initial price applicability year 2028 and all subsequent years , the period before a small-molecule drug is eligible for negotiation will be extended to 11 years, aligning it with the period typically afforded to biologics.